Menu Search
Equities

Bayer AG

BAYRY:PKC

Bayer AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.80
  • Today's Change0.120 / 1.56%
  • Shares traded1.57m
  • 1 Year change-51.31%
  • Beta1.0688
Data delayed at least 15 minutes, as of May 09 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 02-May-24
Select bar for recommendation details.
Recommendations02-May-24
Buy1
Outperform0
Hold0
Underperform1
Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Bayer AG (ADR) have a median target of 28.89, with a high estimate of 50.18 and a low estimate of 7.60. The median estimate represents a 270.38% increase from the last price of 7.80.
High543.3%50.18
Med270.4%28.89
Low-2.6%7.60

Dividends

Historical dividend information is not available for Bayer AG.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Mar 05, 2024, Bayer AG (ADR) reported 4th quarter 2023 earnings of 0.498 per share. This result exceeded the 0.45 expectation of the one analyst covering the companyand exceeded last year's 4th quarter results by 43.52%.
The next earnings announcement is expected on May 14, 2024.
Average growth rate+96.29%
Bayer AG (ADR) reported annual 2023 earnings of 1.73 per share on Mar 05, 2024.
Average growth rate-0.36%
More ▼

Revenue history & estimates in USD

Bayer AG (ADR) had 4th quarter 2023 revenues of 12.76bn. This missed the 13.14bn estimate of the one analyst following the company. This was 22.24% below the prior year's 4th quarter results.
Average growth rate+5.22%
Bayer AG (ADR) had revenues for the full year 2023 of 51.50bn. This was 3.37% below the prior year's results.
Average growth rate+1.54%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.